Press Releases

Date Title and Summary
Jun 01, 2023

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE ® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million , an Increase of 17% YoY Forecasts FYCOMPA ® 2023 Net Product Revenue of Approximately $130 Million for 11 Months
May 30, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

CORAL GABLES, Fla. , May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today
May 10, 2023

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms Full Year Total Revenue Guidance of Between $375 Million
May 09, 2023

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla. , May 09, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on
May 01, 2023

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

CORAL GABLES, Fla. , May 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced
Apr 24, 2023

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET CORAL GABLES, Fla. , April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
Apr 20, 2023

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

CORAL GABLES, Fla. , April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare
Mar 15, 2023

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Achieved Record 2022 Total Net Revenues of $214 Million , a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million , a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of 2023 Total Net Product
Mar 08, 2023

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

CORAL GABLES, Fla. , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare
Mar 01, 2023

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET CORAL GABLES, Fla. , March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

Displaying 1 - 10 of 15